Cormedix Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CORMEDIX, and what generic alternatives to CORMEDIX drugs are available?
CORMEDIX has one approved drug.
There are four US patents protecting CORMEDIX drugs.
There are twelve patent family members on CORMEDIX drugs in eight countries.
Summary for Cormedix
| International Patents: | 12 |
| US Patents: | 4 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Cormedix
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cormedix | DEFENCATH | heparin sodium; taurolidine | SOLUTION;N/A | 214520-001 | Nov 15, 2023 | RX | Yes | Yes | 8,541,393 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
| Cormedix | DEFENCATH | heparin sodium; taurolidine | SOLUTION;N/A | 214520-002 | Nov 15, 2023 | RX | Yes | Yes | 11,738,120 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
| Cormedix | DEFENCATH | heparin sodium; taurolidine | SOLUTION;N/A | 214520-002 | Nov 15, 2023 | RX | Yes | Yes | 8,541,393 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
| Cormedix | DEFENCATH | heparin sodium; taurolidine | SOLUTION;N/A | 214520-002 | Nov 15, 2023 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | |||||
| Cormedix | DEFENCATH | heparin sodium; taurolidine | SOLUTION;N/A | 214520-002 | Nov 15, 2023 | RX | Yes | Yes | 9,339,036 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
| Cormedix | DEFENCATH | heparin sodium; taurolidine | SOLUTION;N/A | 214520-001 | Nov 15, 2023 | RX | Yes | Yes | 9,339,036 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Cormedix
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Cormedix | DEFENCATH | heparin sodium; taurolidine | SOLUTION;N/A | 214520-001 | Nov 15, 2023 | 8,541,393 | ⤷ Subscribe |
| Cormedix | DEFENCATH | heparin sodium; taurolidine | SOLUTION;N/A | 214520-002 | Nov 15, 2023 | 9,339,036 | ⤷ Subscribe |
| Cormedix | DEFENCATH | heparin sodium; taurolidine | SOLUTION;N/A | 214520-002 | Nov 15, 2023 | 8,541,393 | ⤷ Subscribe |
| Cormedix | DEFENCATH | heparin sodium; taurolidine | SOLUTION;N/A | 214520-001 | Nov 15, 2023 | 9,339,036 | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Cormedix Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2013090933 | ⤷ Subscribe |
| World Intellectual Property Organization (WIPO) | 2023201019 | ⤷ Subscribe |
| Japan | 2008518739 | ⤷ Subscribe |
| Spain | 2951567 | ⤷ Subscribe |
| European Patent Office | 1814562 | ⤷ Subscribe |
| European Patent Office | 2742945 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
